Roth Capital Cuts BioHarvest Sciences (NASDAQ:BHST) Price Target to $8.00

BioHarvest Sciences (NASDAQ:BHST) had its target price trimmed by Roth Capital from $10.00 to $8.00 in a report published on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other research analysts also recently commented on the stock. Weiss Ratings raised shares of BioHarvest Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 18th. Maxim Group cut their price target on shares of BioHarvest Sciences from $12.00 to $5.00 and set a “buy” rating on the stock in a report on Wednesday. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, BioHarvest Sciences currently has an average rating of “Hold” and an average price target of $6.50.

BioHarvest Sciences Price Performance

Shares of NASDAQ:BHST opened at $2.07 on Wednesday. The stock has a market cap of $40.61 million, a price-to-earnings ratio of -3.98 and a beta of 0.97. The business’s 50 day moving average is $2.66 and its 200 day moving average is $3.74. BioHarvest Sciences has a 12-month low of $1.82 and a 12-month high of $12.80.

BioHarvest Sciences (NASDAQ:BHST) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.04). BioHarvest Sciences had a negative return on equity of 58.30% and a negative net margin of 31.21%.The firm had revenue of $8.84 million during the quarter, compared to analysts’ expectations of $9.45 million. As a group, equities research analysts expect that BioHarvest Sciences will post -0.58 earnings per share for the current year.

Institutional Investors Weigh In On BioHarvest Sciences

Large investors have recently made changes to their positions in the stock. Alyeska Investment Group L.P. purchased a new stake in shares of BioHarvest Sciences in the 4th quarter valued at $3,929,000. Thompson Siegel & Walmsley LLC purchased a new position in BioHarvest Sciences in the 4th quarter valued at $1,945,000. Evercore Wealth Management LLC acquired a new stake in BioHarvest Sciences during the 4th quarter worth $724,000. True North Advisors LLC boosted its stake in BioHarvest Sciences by 381.0% during the 1st quarter. True North Advisors LLC now owns 168,013 shares of the company’s stock worth $729,000 after purchasing an additional 133,085 shares during the last quarter. Finally, King Luther Capital Management Corp purchased a new stake in shares of BioHarvest Sciences during the fourth quarter worth $208,000.

Trending Headlines about BioHarvest Sciences

Here are the key news stories impacting BioHarvest Sciences this week:

• Positive Sentiment: Maxim Group reaffirmed its Buy rating on BioHarvest Sciences, signaling continued confidence in the company’s longer-term prospects despite near-term earnings pressure. Maxim Group Reaffirms Their Buy Rating on BioHarvest Sciences
• Neutral Sentiment: BioHarvest’s Q2 2026 earnings-call transcript gives investors additional detail on management’s operating plans and outlook, but the supplied information does not identify a specific new catalyst. BioHarvest Sciences Q2 2026 Earnings Call Transcript
• Negative Sentiment: HC Wainwright lowered EPS forecasts across every reported period. Estimates were reduced to losses of $0.18 for Q3 2026, $0.15 for Q4, $0.59 for FY2026 and $0.41 for FY2027. The firm also cut FY2028 from a $0.26 profit to a $0.01 loss, FY2029 from $0.83 to $0.44, and FY2030 from $1.50 to $0.99. The revisions suggest slower progress toward profitability and weaker long-term earnings potential.
• Negative Sentiment: Roth Capital also lowered its expectations for BHST’s stock price, adding to the cautious analyst tone. Roth Capital Has Lowered Expectations for BioHarvest Sciences Stock Price
• Negative Sentiment: The company’s latest reported quarter showed additional execution risk: EPS was a $0.17 loss versus the $0.13 expected loss, while revenue of $8.84 million fell short of the $9.45 million consensus estimate. BHST also remains unprofitable, with analysts expecting a full-year loss.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.